Commit To Purchase Tango Therapeutics At $10, Earn 25.9% Annualized Using Options

Tango Therapeutics (TNGX) December $10 put can be sold for a $2.25 premium, implying a 25.9% annualized return while the stock trades at $11.97; the contract would only be exercised if shares fall ~16.3%, producing an effective cost basis of $7.75 if assigned. Trailing-12-month volatility is 102%, highlighting substantial option risk and limited upside for the put seller (premium only), so the trade is a yield-seeking, downside-risk exposure that should be evaluated alongside Tango's fundamentals before deployment.

Analysis

Market structure: The immediate beneficiary of the trade described is the option seller collecting a $2.25 premium on a $10 strike (current TNGX $11.97) which annualizes to ~25.9%; market-makers and brokers also collect fees. Losers are punters who misprice binary biotech risk — if TNGX falls >16.3% to $10 the seller is assigned and ends up owning stock at an effective $7.75; with trailing vol ~102% the one‑sigma move over ~10 months is roughly ~90%, so assignment risk is material. Cross‑asset impact is limited but heightened biotech vols can push risk‑off flows into credit and widen small‑cap spreads.

Key Decisions for Investors

• Trade: Sell a defined‑risk put spread on TNGX — sell Dec $10, buy Dec $7.50 — size to 0.5–1.0% of portfolio notional to collect premium while capping downside to ~$2.50/share; close or roll if spread cost >50% of max loss or if implied vol >150% (sign of realized shock).
• Allocation: If comfortable owning TNGX, establish a 1–2% long-equity exposure by selling up to desired notional of Dec $10 naked puts (effective purchase price $7.75); set a hard stop: cut assignment/holdings if share price < $6.50 or if a dilutive financing is announced within 90 days.
• Hedge/sector: Reduce broad small‑biotech exposure by buying XBI 3‑month 10% OTM puts (~1–2% portfolio) or short XBI equal to 1% notional to hedge against sector skid should clinical/regulatory news worsen.
• Due diligence trigger: Before any size increase, require two firm checks within 30 days — (1) cash runway disclosure covering ≥12 months or committed financing, (2) calendar of clinical readouts/IND/filings for the next 90 days; if either is negative, close put sellers and convert to protective spreads.